Introduction
============

Pancreatic ductal adenocarcinoma (PDAC) is known as one of the most malignant types of neoplasm, with a 5-year survival rate of \<6%. In addition, there is an increasing number of patients diagnosed annually with *de novo* PDAC ([@b1-ol-0-0-10822],[@b2-ol-0-0-10822]). Although radical resection provides a chance of successful treatment, only 15--20% of patients with PDAC are candidates for radical resection at the time of diagnosis ([@b3-ol-0-0-10822]--[@b5-ol-0-0-10822]). The majority of unresectable patients present with distant metastasis and others present with tumor invasion of surrounding vessels ([@b6-ol-0-0-10822]).

In the past, patients with portal vein (PV) involvement were deemed unresectable because PV invasion would be a harbinger of metastatic disease and early attempts of pancreaticoduodenectomy (PD) with PV resection (PVR) were always coupled with worse survival time (211 vs. 374 days; P\<0.001) ([@b7-ol-0-0-10822]). With the development of vascular reconstruction technique, PD combined with PVR has been gradually carried out for selected patients with PDAC with PV involvement ([@b8-ol-0-0-10822]). However, there remains a debate on whether it is worthwhile to perform PD synchronously with PVR knowing that local recurrence is not common in patients with PV invasion ([@b9-ol-0-0-10822]). A number of studies demonstrated that PD with PVR provided no significant survival benefit at the expense of higher rates of morbidity and mortality ([@b10-ol-0-0-10822]--[@b12-ol-0-0-10822]), while others argued that PD with PVR was safe and feasible and could offer improved survival outcomes ([@b13-ol-0-0-10822]--[@b16-ol-0-0-10822]).

A recent systemic review reported that the median overall survival (OS) time was worse in patients with PVR (14.3 vs. 19.5 months) and the postoperative complication rate was higher (odds ratio, 1.34; P=0.03) ([@b17-ol-0-0-10822]). However, more patients in the PD+PVR group had larger tumors, higher tumor grades, more plexus invasion and greater lymph node (LN) metastasis ([@b18-ol-0-0-10822]--[@b20-ol-0-0-10822]). In addition, there was a notable difference in baseline clinical characteristics between patients with and without PVR ([@b20-ol-0-0-10822]). Due to the poorer clinical characteristics, patients with PVR usually have worse long-term prognosis ([@b20-ol-0-0-10822]).

Given this dilemma, propensity score matching (PSM), which is the conditional probability of assignment to a particular treatment given a vector of observed covariate ([@b21-ol-0-0-10822]), has been widely used to balance the baselines between the experimental group and control group ([@b22-ol-0-0-10822],[@b23-ol-0-0-10822]) for the sake of reducing selection bias and identifying the causal effect ([@b21-ol-0-0-10822],[@b24-ol-0-0-10822]).

It was demonstrated in our previous study that PVR could significantly improve the OS of patients with PV involvement as compared with chemotherapy or surgical bypass ([@b25-ol-0-0-10822]). However, comparisons between patients with or without PVR, to the best of our knowledge, have not been reported. The aim of the present study was to compare the survival outcomes between patients with or without PVR by using the PSM method. This was done to determine whether patients with PV involvement could achieve the same survival benefit from PVR as patients without PV involvement, in order to verify the efficacy and safety of PVR.

Patients and methods
====================

### Inclusion and exclusion criteria

The inclusion criteria for the patients enrolled in the present study were as follows: i) Age \>18 years; ii) patients diagnosed with histopathologically confirmed resectable PDAC; and iii) patients who underwent PD with or without PVR. The exclusion criteria were as follows: i) Patients with severe medical comorbidities and other uncontrolled malignancies; and ii) patients with peri- or intra-operative evidence of distant metastasis and arterial involvement. Before PSM, 377 patients (PVR group, n=138; non-PVR group, n=239) from Huashan Hospital (Shanghai, China) were enrolled in the present study from January 2011 to December 2013. Among which, 231 patients were males (mean age, 61.8±8.7 years; range, 34--84 years) and 146 patients were females (mean age, 62.3±8.8 years; range, 29--84 years). After PSM, 246 patients (PVR group, n=123; non-PVR group, n=123) from Huashan Hospital (Shanghai, China) were enrolled into the present study. Among which, 151 patients were males (mean age, 62.0±9.2 years; range, 35--84 years) and 95 patients were females (mean age, 62.8±9.7 years; range, 29--83 years).

Tumor stage was assessed pathologically according to the Tumor-Node-Metastasis (TNM) classification system published by the American Joint Committee on Cancer, 8th edition ([@b26-ol-0-0-10822]). This study was approved and performed in accordance with the Declaration of Helsinki and the Clinical Research Ethics Committee of Huashan Hospital. All patients signed informed consent for surgical treatment and pathological examinations.

### Preoperative detection and evaluation

Ultrasonography, computed tomography (CT), MRI, positron emission tomography-CT (PET-CT) and endoscopic sonography were performed to evaluate local tumor extension and metastasis. A high suspicion of PV involvement based on preoperative imaging, such as CT or MRI, was determined. Nevertheless, the surgeon\'s intraoperative visual judgments were also of great importance to determine the possibility of PV involvement. Patient demographics \[serum leukocyte count, serum alanine aminotransferase (ALT), total bilirubin (TBil), albumin (ALB), body mass index (BMI), serum carbohydrate antigen (CA)125 and CA19-9\], tumor characteristics, intra-operative parameters and patient survival were compared between the two groups.

### Surgical procedures

Patients with resectable primary tumors and preoperative evaluation of PV involvement ([@b27-ol-0-0-10822]) were divided into a PD+PVR group and a PD group. All patients enrolled in this study underwent detailed preoperative examination, including both blood tests and imageological examinations (CT, MRI or PET-CT). Patients with suspected metastasis were confirmed by pathological evidence (biopsy or operation) and were excluded from this study. During the operation, the surgeon\'s own visual judgments and intraoperative ultrasound was used to detect remote metastasis. Patients with any extra-pancreatic metastasis, which were not detected by preoperative PET-CT scanning, were also excluded from this study. Patients with PV involvement, but without possibility of reconstruction (multiple branch involvement), underwent surgical bypass (SB) procedure based on intra-operative judgment of the surgeon, and were also excluded from this study.

In the PD group, patients underwent classical PD. In the PD+PVR group, patients with PV involvement underwent radical resection of PDAC and PVR. PVR was carried out *en-bloc* as primary closure of the vein, and reconstructed with ePTFE vascular grafts (Bard Peripheral Vascular, Inc.).

### Follow-up observation and complications

During the follow-up period (the last follow-up date was December 2018), all patients were followed up for CT and blood tests, and patients with PVR required an additional ultrasound to detect patency of the artificial grafts. Patients were followed up monthly postoperatively for the first 6 months, then every 3--6 months thereafter. All patients in PVR group were administrated aspirin (100 mg a day) and received ultrasound examinations postoperatively. OS time was the primary outcome of this study. Postpancreatectomy hemorrhage (PPH), postoperative pancreatic fistula (POPF), chylous fistula and delayed gastric emptying (DGE) were defined according to International Study Group of Pancreatic Surgery ([@b28-ol-0-0-10822]--[@b31-ol-0-0-10822]). In the present study, all patients died from disease.

### PSM analysis

There were statistically significant differences in the baseline characteristics between the two groups, which would affect the outcome of analysis. For continuous data, differences between the two groups were analyzed using the independent Student\'s t-test, and a χ^2^ test was used for categorical variables. PSM was utilized to balance the baseline characteristics between the two groups, in order to reduce the risk of selection bias and mimic a controlled randomized trial. A logistic regression model was used to estimate PSM based on age, sex, BMI, leukocyte, ALT, TBil, ALB, CA125, CA19-9, tumor stage, LN metastasis and tumor size. One-to-one matching without replacement conducted by a 0.1 caliper matching on the estimated propensity score generated 123 matched PVR and non-PVR units ([@b32-ol-0-0-10822]).

### Statistical analysis

All demographic and clinicopathological data were collected in the computer database of Huashan Hospital and analyzed statistically using SPSS 23.0 (IBM, Corp.). In the case of continuous data, differences between the two groups were analyzed through the independent Student\'s t-test, and a χ^2^ test was used for categorical variables. Survival curves were established using the Kaplan-Meier method and compared with a log-rank test. Continuous data were reported as mean ± standard error. Significant risk factors were first identified using univariate logistic regression, after which the significant univariate factors were further examined using multivariate analysis. The outcomes were presented using hazard ratios (HRs) and associated 95% confidence intervals (CIs). A two-sided P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographic and clinicopathological parameters of the included patients before PSM

Between 2011 and 2013, there were 138 patients who underwent PD+PVR and the remaining 239 received PD without PVR. Patients in the PD+PVR group exhibited more tumor stage II patients (P\<0.001), smaller BMIs (P=0.015), significantly higher CA19-9 levels (P=0.040), significantly lower CA125 levels (P=0.010), larger tumor sizes (P\<0.001), longer operating durations (P\<0.001) and more intraoperative blood loss (P\<0.001) ([Table I](#tI-ol-0-0-10822){ref-type="table"}).

### Survival analysis before PSM analysis

Multivariate Cox regression model showed that advanced tumor stages, lower BMI levels, LN metastasis, lower ALB levels, higher CA125 and CA19-9 levels were independent prognostic factors ([Table II](#tII-ol-0-0-10822){ref-type="table"}).

Survival analysis revealed that patients in the PVR group had significantly worse survival outcomes compared with patients in the non-PVR group (mean survival, 25.1 vs. 29.3 months; P=0.038; [Fig. 1](#f1-ol-0-0-10822){ref-type="fig"}). A number of other factors associated with OS, such as TNM stage, BMI, ALB and LN metastasis, were further analyzed as indicated in [Fig. 1](#f1-ol-0-0-10822){ref-type="fig"}.

Logistic regression analysis identified two risk factors that could predict PV invasion: advanced tumor stages (HR, 20.439; 95% CI, 4.166--100.271; P\<0.001) and higher CA19-9 levels (HR, 6.608; 95% CI, 2.064--21.154; P=0.001).

### Demographic and clinicopathological parameters of the included patients after PSM

A total of 123 matched pairs of patients from the PD+PVR and non-PVR groups were confirmed via PSM based on age, sex BMI, leukocyte, ALT, TBil, ALB, CA125, CA19-9, tumor stage, LN metastasis and tumor size. After PSM, a number of factors, which may imply patients\' pre-operative general status and have an effect on survival, were balanced including age, BMI, ALB, CA125, CA19-9, tumor stage, LN metastasis and tumor size ([Table I](#tI-ol-0-0-10822){ref-type="table"}).

### Survival analysis after PSM

Multivariate Cox regression model showed that advanced tumor stages, lower BMI levels, R1 resection (microscopic positive margin), LN metastasis, lower ALB levels, higher CA125 and CA19-9 levels were independent prognostic factors ([Table II](#tII-ol-0-0-10822){ref-type="table"}).

Survival analysis showed that the survival outcome of patients in the PD+PVR group was similar to that of patients in the non-PVR group (mean survival, 25.9 vs. 31.2 months; P=0.364; [Fig. 2](#f2-ol-0-0-10822){ref-type="fig"}). Other factors such as TNM stage, LN metastasis, BMI, ALB, R1 resection, CA125 and CA19-9 associated with OS were further analyzed and were shown in [Fig. 2](#f2-ol-0-0-10822){ref-type="fig"}.

Logistic regression analysis also identified advanced tumor stage (HR, 17.827; 95% CI, 3.627--87.627; P\<0.001) and higher CA19-9 levels (HR, 6.913; 95% CI, 2.124--22.503; P=0.001) as the same two risk factors predicting PV invasion.

### Subgroup analysis in the PD+PVR group

Regardless to prior or latter PSM, patients with PV invasion, advanced tumor stage, R1 resection, lower BMI levels, lower ALB levels, LN metastasis, lower CA125 and CA19-9 levels had poorer prognostic outcomes ([Table SI](#SD1-ol-0-0-10822){ref-type="supplementary-material"}; [Figs. S1](#SD1-ol-0-0-10822){ref-type="supplementary-material"} and [S2](#SD1-ol-0-0-10822){ref-type="supplementary-material"}).

### Subgroup analysis in non-PVR group

The results still indicated that patients with advanced tumor stage, R1 resection, LN metastasis, lower CA125 and CA19-9 levels had poorer prognostic outcomes, regardless to prior or latter PSM. Lower ALB levels and lower BMI did not indicate a worse prognosis in the non-PVR group ([Table SII](#SD1-ol-0-0-10822){ref-type="supplementary-material"}; [Figs. S3](#SD1-ol-0-0-10822){ref-type="supplementary-material"} and [S4](#SD1-ol-0-0-10822){ref-type="supplementary-material"}).

### Postoperative complications

Patients in the PD+PVR group did not have a significantly higher overall complication rate or more severe complications compared with patients in the non-PVR group (all P\>0.05). The postoperative complications in PD+PVR and non-PVR groups were combined and the most frequent complication was POPF (n=220; 58.4%). Other complications were chylous fistula in 10 patients (2.7%), DGE in 44 patients (11.7%), PPH in 22 patients (5.8%), wound infection in 47 patients (12.5%), pleural effusion in 67 patients (17.8%) and abdominal infection in 11 patients (2.9%) before PSM. After PSM, the most frequent combined complication remained POPF (n=133; 54.1%), and other complications were chylous fistula in 3 patients (1.2%), DGE in 27 patients (11.0%), PPH in 9 patients (3.7%), wound infection in 25 patients (10.2%), pleural effusion in 44 patients (17.9%) and abdominal infection in 9 patients (3.7%) ([Table III](#tIII-ol-0-0-10822){ref-type="table"}). There was no 30-day mortality indicated in either group. Furthermore, no graft infection, thrombosis, or serious graft-related complication has been reported in patients in the PVR group.

Discussion
==========

Growing evidence has demonstrated that PV resection is safe for the treatment of patients with borderline resectable PDAC ([@b33-ol-0-0-10822]--[@b35-ol-0-0-10822]). PD combined with PVR is the only radical therapy for PDAC patients with PV involvement at present ([@b7-ol-0-0-10822]). Our previous study demonstrated that patients with radical resection of PDAC and PVR had significantly improved survival compared with patients with chemotherapy or SB alone ([@b25-ol-0-0-10822]). However, other studies drew controversial conclusions after comparing the survival between patients with PVR and patients undergoing pancreatectomy alone ([@b7-ol-0-0-10822],[@b16-ol-0-0-10822],[@b36-ol-0-0-10822]--[@b44-ol-0-0-10822]). This discrepancy between different studies may mainly be due to huge heterogenicity of patients between the study and control groups. In the present study, the PSM method was used to balance the baseline characteristics between the PVR and non-PVR groups, and it was indicated that patients with PD combined with PVR could achieve the same survival outcome as patients without PVR.

In patients with PV invasion, tumor cells are more likely to invade the host stroma, penetrate blood vessels and enter the circulation to produce metastasis by forming new colonies in distant organs ([@b45-ol-0-0-10822]). We hypothesize that this may be the reason for patients with PVR to have significantly worse survival outcomes. In the present study, it was indicated that before PSM, patients in the PVR group had poor survival outcomes compared with patients in the non-PVR group. However, it was identified that the poor prognosis may be due to the fact that patients in the PVR group were accompanied with higher CA19-9 levels, advanced tumor stages and bigger tumor sizes. All these factors imply that patients in the PVR group were at a more advanced stage of the disease, and certainly with a worse survival outcome (P=0.038). In order to eliminate selection bias between the two groups, the PSM method was used. After PSM, although patients in the PVR group still had longer operation durations and more blood loss, the other factors were balanced as expected. The patients in the PVR group achieved the same survival outcomes as the patients in the non-PVR group (P=0.364), indicating that heterogeneity of the baseline characteristics between the two groups did have a potential effect on survival. Through PSM, the current study balanced the heterogeneity and provided a reliable conclusion.

Other than the unbalanced baseline characteristics, we hypothesize that the method of resection and reconstruction may also have an effect on survival. In the present study, the patients in the PVR group underwent radical resection of the primary PDAC, PV resection and reconstruction with artificial blood vessels (ePTFE vascular grafts). For PV reconstruction, self-anastomosis, autogenous and allograft vessel grafts were used in different circumstances ([@b25-ol-0-0-10822]). In the current study, artificial blood vessels (ePTFE vascular grafts) were used for reconstruction, in order to achieve the optimum tumor-free margin. Notably, initial literature research demonstrated that all studies reporting that patients with PVR, who suffered significantly poor survival outcomes, were actually studies reporting that positive surgical margin rate of patients with PVR, who underwent self-anastomosis for PV reconstruction, was relatively high (30--50%) ([@b46-ol-0-0-10822]--[@b48-ol-0-0-10822]). In the present study, the R1 resection rate was 3.6% in the PVR group compared with 5.9% in the non-PVR group (P=0.465). This lower R1 resection rate may to some extent be due to the artificial blood vessels. With the artificial blood vessels, the tension of the reconstructed PV and the length of resected PV were no longer a problem for surgeons during the operation, therefore securing the radical resection of the primary PDAC and invaded PV. However, this study did not compare the benefits between autografts and allografts and therefore further multiple-center studies are required.

The biggest concern for the use of PVR is safety. The complications between patients with PVR and patients with no PVR were compared and it was indicated that regardless of PSM status, there was no significant difference in the complication rate in terms of POPF, chylous fistula, DGE, PPH, wound infection, pleural effusion and abdominal infection between the two groups. Therefore, this study suggested that PVR did not increase the incidence of serious surgical complications. Previous studies have reported that the use of artificial vascular grafts may run a potential risk of infection and thrombosis ([@b49-ol-0-0-10822],[@b50-ol-0-0-10822]). In the present study, all patients in PVR group were administrated aspirin and received ultrasound examinations. To the best of our knowledge, no graft infection, thrombosis, or serious graft-related complication has been reported. The aforementioned suggests that PD combined with PVR and reconstruction with artificial blood vessels is a safe and viable option for the treatment of patients with PV invasion.

The biggest limitation of the current study was its retrospective nature, although attempts were made to reduce or eliminate the bias by utilizing the PSM method and enlarging the sample size. It was indicated that the baseline characteristics were well balanced after using the PSM method. To the best of our knowledge, there is no prospective study design dealing with this issue and therefore the present study is the only one to conduct a comparison between patients with or without PVR using the PSM method. Secondly, no comparison between patients with autograft and allograft was conducted in the present study. Future multi-center research will focus on such clinical experience and perform respective comparisons.

In conclusion, PVR may offer patients with PV involvement the same survival outcome as patients without PV involvement, without increasing the incidence of serious complications. PVR is a safe and viable option for patients with PDAC and is effective for patients with PDAC with suspected PV invasion.
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###### 

Baseline characteristics of all patients who received PD with or without PVR.

                                  Before PSM                                           After PSM                                                       
  ------------------------------- -------------------------- ------------------------- ----------- ------------------------- ------------------------- ---------
  Male, n (%)                     78 (56.5)                  153 (64.0)                0.150       69 (56.1)                 82 (66.7)                 0.089
  Age, years                      62.75±8.22                 61.54±9.01                0.197       62.70±8.53                61.95±10.22               0.534
  BMI, kg/m^2^                    21.70±2.91                 22.41±2.56                0.015       21.80±2.95                21.80±2.53                0.996
  Leukocyte, 109/l                5.82±1.67                  5.82±1.84                 0.966       5.91±1.68                 5.95±1.86                 0.861
  ALT, U/l                        35.50 (18.00--79.25)       45.00 (21.00--84.00)      0.904       39.00 (19.00--82.00)      51.00 (21.00--115.00)     0.302
  TBIL, µmol/l                    13.00 (8.00--31.13)        13.70 (7.60--38.60)       0.660       13.00 (8.00--31.00)       21.70 (10.60--43.80)      0.226
  ALB, g/l                        39.24±4.56                 39.62±3.76                0.383       39.20±4.56                39.12±3.84                0.892
  CA125, U/ml                     14.50 (10.00--40.00)       18.00 (12.00--26.00)      0.010       14.00 (10.00--38.00)      17.00 (12.00--31.00)      0.413
  CA19-9, U/ml                    120.00 (36.75--642.25)     86.00 (40.00--218.00)     0.040       115.00 (40.00--642.00)    100.00 (41.00--438.00)    0.795
  TNM stage, n (%)                                                                                                                                     
    Stage I                       30 (21.7)                  106 (44.4)                \<0.001     30 (24.4)                 33 (26.8)                 0.556
    Stage II                      96 (69.6)                  114 (47.7)                            84 (68.3)                 77 (62.6)                 
    Stage III                     12 (8.7)                   19 (7.9)                              9 (7.3)                   13 (10.6)                 
  LN metastasis, n (%)            66 (47.8)                  96 (40.2)                 0.148       56 (45.5)                 58 (47.2)                 0.798
  Tumor size, cm                  4.06±1.22                  3.13±1.13                 \<0.001     3.87±1.08                 3.71±1.15                 0.254
  R1 resection, n (%)             5 (3.6)                    14 (5.9)                  0.465       5 (4.1)                   7 (5.7)                   0.898
  PV invasion, n (%)              127 (92.0)                 --                        --          112 (91.1)                --                          --
  Operating time, min             485.29±76.52               399.95±72.56              \<0.001     482.76±76.11              433.80±73.37              \<0.001
  Intraoperative blood loss, ml   600.00 (500.00--1000.00)   460.00 (400.00--600.00)   \<0.001     600.00 (500.00--900.00)   460.00 (400.00--800.00)   \<0.001
  Hospital stay, days             21.36±9.20                 19.76±9.67                0.314       21.80±9.55                22.34±9.35                0.652

PSM, propensity score matched; PD, pancreatoduodenectomy; PVR, portal vein resection; TNM, Tumor-Node-Metastasis; BMI, body mass index; ALT, alanine transaminase; TBIL, total bilirubin; ALB, albumin; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; LN, lymph node.

###### 

Multivariate regression analysis of prognostic factors.

                  Before PSM   After PSM                                       
  --------------- ------------ -------------- --------- ------- -------------- -------
  Therapy                                                                      
    PVR           1.084        0.831--1.415   0.551     --      --             --
    Non-PVR                                                                    
  TNM stage                                                                    
    Stage I       1.643        1.214--2.225   0.001     1.912   1.319--2.771   0.001
    Stage II                                                                   
    Stage III                                                                  
  BMI, kg/m^2^                                                                 
    \<18.5        0.652        0.436--0.974   0.037     0.601   0.388--0.931   0.023
    ≥18.5                                                                      
  R1 resection                                                                 
    No            1.685        0.957--2.966   0.071     1.955   1.018--3.755   0.044
    Yes                                                                        
  LN metastasis                                                                
    Yes           0.646        0.465--0.898   0.009     0.642   0.440--0.936   0.021
    No                                                                         
  ALB, g/l                                                                     
    \<35          0.568        0.371--0.868   0.009     0.569   0.350--0.923   0.022
    ≥35                                                                        
  CA125 U/ml                                                                   
    \<35          1.475        1.082--2.011   0.014     1.49    1.038--2.139   0.031
    ≥35                                                                        
  CA19-9 U/ml                                                                  
    \<37          1.708        1.396--2.089   \<0.001   1.485   1.178--1.872   0.001
    37--200                                                                    
    \>200                                                                      

BMI, body mass index; HR, hazard ratio; CI, confidence interval; TNM, Tumor-Node-Metastasis; PSM, propensity score matched; PVR, portal vein resection; ALB, albumin; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; LN, lymph node.

###### 

Complications of the PVR and non-PVR groups.

                            Before PSM                After PSM                             
  ------------------------- ------------ ------------ ----------- ------------ ------------ ---------
  POPF, n (%)                                                                               
    None                    64 (46.4)    93 (38.9)    0.456       63 (51.3)    50 (40.7)    0.365
    Biochemical leak        49 (35.5)    96 (40.2)                40 (32.5)    47 (38.2)    
    Grade B POPF            23 (16.7)    48 (20.1)                19 (15.4)    25 (20.3)    
    Grade C POPF            2 (1.4)      2 (0.8)                  1 (0.8)      1 (0.8)      
  Chylous fistula, n (%)                                                                    
    None                    136 (98.6)   231 (96.6)   0.702       122 (99.2)   121 (98.4)   \>0.999
    Grade A                 0 (0.0)      1 (0.4)                  0 (0.0)      0 (0.0)      
    Grade B                 2 (1.4)      7 (3.0)                  1 (0.8)      2 (1.6)      
    Grade C                 0 (0.0)      0 (0.0)                  0 (0.0)      0 (0.0)      
  DGE, n (%)                                                                                
    None                    125 (90.6)   208 (87.0)   0.809       111 (90.2)   108 (87.8)   0.906
    Grade A                 7 (5.1)      16 (6.7)                 7 (5.7)      8 (6.5)      
    Grade B                 5 (3.6)      11 (4.6)                 4 (3.3)      6 (4.9)      
    Grade C                 1 (0.7)      4 (1.7)                  1 (0.8)      1 (0.8)      
  PPH, n (%)                                                                                
    None                    132 (95.7)   223 (93.4)   0.496       119 (96.8)   118 (96.0)   \>0.999
    Grade A                 3 (2.2)      12 (5.0)                 2 (1.6)      3 (2.4)      
    Grade B                 1 (0.7)      2 (0.8)                  1 (0.8)      1 (0.8)      
    Grade C                 2 (1.4)      2 (0.8)                  1 (0.8)      1 (0.8)      
  Wound infection, n (%)                                                                    
    None                    122 (88.4)   208 (87.0)   0.697       111 (90.2)   110 (89.4)   0.833
    Yes                     16 (11.6)    31 (13.0)                12 (9.8)     13 (10.6)    
  Pleural effusion, n (%)                                                                   
    None                    112 (81.2)   198 (82.8)   0.680       102 (82.9)   100 (81.3)   0.739
    Yes                     26 (18.8)    41 (17.2)                21 (17.1)    23 (18.7)    

PSM, propensity score matched; PVR, portal vein resection; POPF, postoperative pancreatic fistula; DGE, delayed gastric emptying; PPH, postpancreatectomy hemorrhage.

[^1]: Contributed equally
